EP4054567A4 - Behandlung von lebererkrankungen - Google Patents
Behandlung von lebererkrankungen Download PDFInfo
- Publication number
- EP4054567A4 EP4054567A4 EP20886094.0A EP20886094A EP4054567A4 EP 4054567 A4 EP4054567 A4 EP 4054567A4 EP 20886094 A EP20886094 A EP 20886094A EP 4054567 A4 EP4054567 A4 EP 4054567A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treating liver
- liver disorders
- disorders
- treating
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019423 liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962933277P | 2019-11-08 | 2019-11-08 | |
US202063004403P | 2020-04-02 | 2020-04-02 | |
PCT/US2020/059522 WO2021092474A1 (en) | 2019-11-08 | 2020-11-06 | Treating liver disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4054567A1 EP4054567A1 (de) | 2022-09-14 |
EP4054567A4 true EP4054567A4 (de) | 2024-01-10 |
Family
ID=75849579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20886094.0A Pending EP4054567A4 (de) | 2019-11-08 | 2020-11-06 | Behandlung von lebererkrankungen |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4054567A4 (de) |
JP (1) | JP2023501386A (de) |
KR (1) | KR20220098168A (de) |
CN (1) | CN114667142A (de) |
AU (1) | AU2020380968A1 (de) |
BR (1) | BR112022008639A2 (de) |
CA (1) | CA3160445A1 (de) |
CL (1) | CL2022001167A1 (de) |
IL (1) | IL292459A (de) |
MX (1) | MX2022005407A (de) |
WO (1) | WO2021092474A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220184114A1 (en) | 2020-12-14 | 2022-06-16 | Regeneron Pharmaceuticals, Inc. | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019023245A1 (en) * | 2017-07-25 | 2019-01-31 | Cedars-Sinai Medical Center | METHODS OF TREATING HEPATIC DISEASES |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
US20140187633A1 (en) * | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
CA3019496A1 (en) * | 2016-03-28 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Medicine obtained by combining fxr agonist and arb |
WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
KR20210052507A (ko) * | 2018-08-30 | 2021-05-10 | 테른스 파마슈티칼스, 인크. | 간 장애 치료 |
-
2020
- 2020-11-06 MX MX2022005407A patent/MX2022005407A/es unknown
- 2020-11-06 CN CN202080077929.8A patent/CN114667142A/zh active Pending
- 2020-11-06 JP JP2022526136A patent/JP2023501386A/ja active Pending
- 2020-11-06 WO PCT/US2020/059522 patent/WO2021092474A1/en unknown
- 2020-11-06 IL IL292459A patent/IL292459A/en unknown
- 2020-11-06 KR KR1020227018657A patent/KR20220098168A/ko unknown
- 2020-11-06 BR BR112022008639A patent/BR112022008639A2/pt not_active Application Discontinuation
- 2020-11-06 AU AU2020380968A patent/AU2020380968A1/en active Pending
- 2020-11-06 CA CA3160445A patent/CA3160445A1/en active Pending
- 2020-11-06 EP EP20886094.0A patent/EP4054567A4/de active Pending
-
2022
- 2022-05-04 CL CL2022001167A patent/CL2022001167A1/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019023245A1 (en) * | 2017-07-25 | 2019-01-31 | Cedars-Sinai Medical Center | METHODS OF TREATING HEPATIC DISEASES |
Non-Patent Citations (7)
Title |
---|
"Bile Acids and Their Receptors", vol. 256, 14 June 2019, SPRINGER INTERNATIONAL PUBLISHING, Cham, ISBN: 978-3-030-22005-1, article GEGE CHRISTIAN ET AL: "Nonsteroidal FXR Ligands: Current Status and Clinical Applications", pages: 167 - 205, XP093103470, DOI: 10.1007/164_2019_232 * |
ANONYMOUS: "Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting 2019 | Business Wire", 15 October 2019 (2019-10-15), pages 1 - 2, XP093103551, Retrieved from the Internet <URL:https://www.businesswire.com/news/home/20191015005032/en/Terns-Pharmaceuticals-to-Present-Positive-Preclinical-Data-on-FXR-Agonist-TERN-101-at-The-Liver-Meeting -2019> [retrieved on 20231120] * |
CARR ROTONYA M ET AL: "FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease", CURRENT ATHEROSCLEROSIS REPORTS, SPRINGER US, NEW YORK, vol. 17, no. 4, 18 February 2015 (2015-02-18), pages 1 - 14, XP035470130, ISSN: 1523-3804, [retrieved on 20150218], DOI: 10.1007/S11883-015-0500-2 * |
GENIN MICHAEL J. ET AL: "Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1 H -indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 24, 14 November 2015 (2015-11-14), US, pages 9768 - 9772, XP055932709, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01161 * |
KLUCHER KEVIN ET AL: "FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis", JOURNAL OF HEPATOLOGY, vol. 70, no. 1, 1 April 2019 (2019-04-01), AMSTERDAM, NL, pages e534, XP093103535, ISSN: 0168-8278, DOI: 10.1016/S0618-8278(19)31056-4 * |
See also references of WO2021092474A1 * |
YUJIN WANG ET AL: "Pharmacokinetics, Tissue Distribution and Pharmacodynamics of TERN-101, a Novel Farnesoid Xreceptor (FXR) Agonist, in Preclinical Species", HEPATOLOGY; AASLD ABSTRACTS, JOHN WILEY & SONS, INC, US, vol. 70, no. Suppl. 1, 1 October 2019 (2019-10-01), pages 1277, XP009550030, ISSN: 0270-9139 * |
Also Published As
Publication number | Publication date |
---|---|
MX2022005407A (es) | 2022-05-24 |
WO2021092474A1 (en) | 2021-05-14 |
JP2023501386A (ja) | 2023-01-18 |
CL2022001167A1 (es) | 2023-02-10 |
KR20220098168A (ko) | 2022-07-11 |
EP4054567A1 (de) | 2022-09-14 |
BR112022008639A2 (pt) | 2022-07-19 |
IL292459A (en) | 2022-06-01 |
CA3160445A1 (en) | 2021-05-14 |
AU2020380968A1 (en) | 2022-05-12 |
CN114667142A (zh) | 2022-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3746135A4 (de) | Verfahren und verbindungen zur behandlung von erkrankungen | |
EP3867745A4 (de) | Hyperpiler | |
EP3833739A4 (de) | Akkormansia muciniphila | |
EP3890748A4 (de) | Zusammensetzungen und verfahren zur behandlung von lebererkrankungen | |
EP3781482A4 (de) | Nano-satellit | |
EP3692023A4 (de) | Benzothiazolverbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen | |
EP3844156A4 (de) | Behandlung von lebererkrankungen | |
EP3658139A4 (de) | Verfahren zur behandlung von lebererkrankungen | |
EP3973047A4 (de) | Verfahren und zusammensetzungen zur behandlung von leberkrankheiten | |
EP3893883A4 (de) | Verfahren zur behandlung von depression | |
EP3902536A4 (de) | Zusammensetzungen und verfahren zur behandlung von neurodegenerativen störungen | |
EP3976107A4 (de) | Sonosensibilisierung | |
EP3773491A4 (de) | Verfahren zur behandlung von apoe4/4-assoziierten erkrankungen | |
EP3793566A4 (de) | Zusammensetzungen und verfahren zur reduktion von spliceopathie und behandlung von rna-dominanzstörungen | |
EP3752161A4 (de) | Verfahren zur behandlung von fibrose | |
EP3952851A4 (de) | Verbindungen und verfahren zur behandlung von entzündlichen erkrankungen | |
EP3934632A4 (de) | Esketamin zur behandlung von depression | |
EP3954368A4 (de) | Verbindung zur behandlung von neurodegenerativen erkrankungen | |
EP4054567A4 (de) | Behandlung von lebererkrankungen | |
EP4003420A4 (de) | Il-38-spezifische antikörper | |
EP3755352A4 (de) | Verfahren und zusammensetzungen zur behandlung von bewegungserkrankungen | |
EP3972606A4 (de) | Behandlung von chronischer lebererkrankung | |
EP3962492A4 (de) | Verfahren zur behandlung neurodegenerativer erkrankungen | |
EP4045046A4 (de) | Verfahren und zusammensetzungen zur behandlung von eisenkrankheiten | |
AU2019900181A0 (en) | Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220511 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231212 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 413/12 20060101ALI20231206BHEP Ipc: C07D 261/08 20060101ALI20231206BHEP Ipc: A61K 31/4545 20060101ALI20231206BHEP Ipc: A61K 31/42 20060101AFI20231206BHEP |